A landmark medical procedure carried out in Panama has demonstrated the potential of remote robotic thrombectomy to transform stroke care worldwide. In March, Felipe Rios Mendoza, a 63-year-old patient suffering from a severe ischemic stroke in Panama City, was treated by a neurosurgeon located 150 miles away in Santiago. Using a robotic system to remove the blood clot blocking Mendoza's brain artery, the procedure marked the world’s first successful remote mechanical thrombectomy on a living patient.

Mendoza was initially assessed with an 80 percent likelihood of death or severe disability due to a clot that had caused paralysis on his right side, loss of speech, and declining consciousness. However, shortly after the intervention performed by Dr. Vitor Mendes Pereira, a professor of medical imaging and surgery at Toronto University, Mendoza began responding and regaining movement. He was discharged within three days and was walking unaided two weeks later. After six months, he had nearly fully recovered.

The robotic platform used in the procedure was developed by XCath Robotics, a US-based technology start-up. Last week, the company’s device received “breakthrough device designation” from the US Food and Drug Administration. XCath Robotics plans to initiate a global clinical trial, including sites in the United Kingdom. CEO Eduardo Fonseca stated that initial operations will be conducted from Toronto, serving patients in Canada and Panama, with ambitions to expand internationally within two years. Interest in participating centres has already emerged from hospitals across England and Scotland.

Mechanical thrombectomy is a well-established stroke treatment performed by guiding a wire through blood vessels to remove clots in the brain, restoring oxygen flow. It significantly improves outcomes for patients experiencing large vessel occlusions, doubling the chance of recovery without disability and reducing mortality by 20 percent when done promptly. Despite this, access remains limited. In England, only 5 percent of stroke patients receive the treatment, with coverage from just 24 hospitals—only 17 offering 24/7 service. Scotland’s provision is even more limited, with only three centres available. Staffing shortages, particularly of interventional neuroradiologists, and the time-sensitive nature of the procedure—ideally within six hours of stroke onset—pose significant challenges.

Remote robotic thrombectomy could address these barriers by allowing specialists to perform the intervention from distant locations, facilitating faster treatment, especially for patients in rural and underserved areas. Professor Iris Grunwald of Dundee University, a pioneer in thrombectomy since 2006, has been trialling a competing remote system, the Sentante platform. Last year, she conducted successful remote procedures on cadavers within her hospital and between Scotland and Florida, demonstrating the feasibility of transatlantic operation. Sentante’s CEO, Edvardas Satkauskas, confirmed ongoing discussions with the National Health Service about potential trials in the UK, possibly starting next year.

Experts emphasize the critical nature of timely intervention in stroke care. Grunwald highlighted that every five to six minutes of delay reduces the likelihood of a good outcome by 1 percent, underscoring the importance of faster access to thrombectomy for remote patients. Juliet Bouverie, chief executive of the Stroke Association, noted that approximately 1.9 million brain cells die each minute a stroke goes untreated, stressing that robotics combined with specialist teams could extend effective treatment to patients in remote locations within crucial timeframes.

As remote robotic thrombectomy progresses through clinical evaluation, it may pave the way for broader access to life-saving stroke interventions, improving recovery prospects for thousands of patients worldwide.